- Home
- LHX vs TAK Comparison
LHX vs TAK Comparison
Compare LHX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LHX
- TAK
- Stock Information
- Founded
- LHX 1895
- TAK 1781
- Country
- LHX United States
- TAK Japan
- Employees
- LHX N/A
- TAK N/A
- Industry
- LHX Industrial Machinery/Components
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- LHX Industrials
- TAK Health Care
- Exchange
- LHX Nasdaq
- TAK Nasdaq
- Market Cap
- LHX 41.4B
- TAK 42.2B
- IPO Year
- LHX N/A
- TAK N/A
- Fundamental
- Price
- LHX $207.74
- TAK $15.06
- Analyst Decision
- LHX Buy
- TAK
- Analyst Count
- LHX 16
- TAK 0
- Target Price
- LHX $260.80
- TAK N/A
- AVG Volume (30 Days)
- LHX 1.3M
- TAK 1.6M
- Earning Date
- LHX 04-24-2025
- TAK 05-08-2025
- Dividend Yield
- LHX 2.31%
- TAK 3.91%
- EPS Growth
- LHX 22.20
- TAK 15.39
- EPS
- LHX 7.87
- TAK 0.83
- Revenue
- LHX $21,325,000,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- LHX $4.71
- TAK $8.53
- Revenue Next Year
- LHX $4.05
- TAK N/A
- P/E Ratio
- LHX $26.40
- TAK $34.20
- Revenue Growth
- LHX 9.81
- TAK 9.83
- 52 Week Low
- LHX $193.09
- TAK $12.58
- 52 Week High
- LHX $265.74
- TAK $15.31
- Technical
- Relative Strength Index (RSI)
- LHX 45.81
- TAK 61.62
- Support Level
- LHX $207.12
- TAK $14.90
- Resistance Level
- LHX $215.35
- TAK $15.17
- Average True Range (ATR)
- LHX 4.31
- TAK 0.18
- MACD
- LHX -0.23
- TAK -0.06
- Stochastic Oscillator
- LHX 21.21
- TAK 46.88
About LHX L3Harris Technologies Inc.
L3Harris Technologies provides products primarily for the command, control, communications, computers, intelligence, surveillance, and reconnaissance, or C4ISR, market. The firm produces uncrewed aerial vehicles, sensors, and avionics, provides military and commercial training services, and maintains the us Federal Aviation Administration's communications infrastructure. In July 2023, the company acquired Aerojet Rocketdyne, a key supplier of rocket motors used in the space industry and to propel munitions.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.